survodutide vs retatrutide tirzepatide: how the next-generation dual agonists actually compare Survodutide vs retatrutide: dual versus

TGF-1: transforming growth factor beta 1

Join now for full access

The most commonly reported side effects in Phase 2 trials are gastrointestinal: nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation

In the STEP 1 extension, patients regained roughly two-thirds of their lost weight within a year of stopping semaglutide (STEP 1 extension, PMC)

Dehydration and renal function : Dehydration resulting from gastrointestinal side effects requires attention, as it can affect overall health, medication levels, and potentially lead to acute kidney injury, especially in those with pre-existing renal impairment

The transformation of monocyte/macrophages into foam cells, is the hallmark of atherogenesis